sosv
(3)
The Pregnancy Test That Could Catch a Killer Before the Doctor Does
Preeclampsia kills tens of thousands of mothers a year, mostly because no one catches it in time. A team that started as classmates in Durham and Kampala wants to move that first warning from the hospital lab to the bathroom shelf.
The Startup Teaching Ventilator Patients to Breathe on Their Own Again
Every long stint on a ventilator quietly weakens the one muscle you need to breathe. XN Health's Phlex device stimulates the phrenic nerve through the breathing tube to keep the diaphragm working - and get patients off the machine sooner.
HexemBio
HexemBio is a New York- and Berkeley-based biotech building what it calls the first blood stem cell rejuvenation therapy. Its Synthetic Human Yolk Sac platform recreates the embryonic environment where blood stem cells first arise, temporarily placing a patient's own aged hematopoietic stem cells into that synthetic young niche before returning them by IV infusion - rather than gene-editing or chemically reprogramming the cells. The company launched publicly in April 2026 with a $10.4M seed round led by Draper Associates, holds an FDA Orphan Drug Designation for a bone-marrow-transplant program in blood cancers, and is targeting first-in-human trials in 2027.